Markov Models for Economic Evaluation in Osteoporosis Treatment

Osteoporosis is frequent in elderly people, causing bone fractures and lowering their quality of life. The costs incurred by these constitute a problem for public health. Markov chains were used to carry out an incremental cost-utility analysis the four main drugs Spain treat osteoporosis (alendronate, risedronate, denosumab teriparatide). We considered 14 clinical transition states, from starting osteoporotic treatment at age 50 until death or 100. Cost-effectiveness was measured adjusted life years (QALYs). values model obtained literature. Teriparatide cost-effective alternative patients with 50, establishing payment threshold 20,000 EUR/QALY. However, it most expensive therapy, not appearing cases that do present fracture ages over 80 fracture. Alendronate therapies are presented as alternatives depending on onset duration treatment. From perspective cost-effectiveness, EUR/QALY, teriparatide 70 old Spain.